{"id":"W4295836740","doi":"10.1016/j.annonc.2022.07.1838","title":"1760P Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Results from patients with ≥12 mo of treatment in JAVELIN Bladder 100","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Bavarian Nordic; Astellas Pharma; Genentech; UroGen Pharma; Foundation Medicine; Silverback Therapeutics; Mirati Therapeutics; Regeneron Pharmaceuticals; Gilead Sciences; Exelixis; GlaxoSmithKline; Bristol-Myers Squibb; AstraZeneca; Pfizer","keywords":"Avelumab; Medicine; Metastatic Urothelial Carcinoma; Javelin; Internal medicine; Chemotherapy; Maintenance therapy; Oncology; Urology; Gastroenterology; Bladder cancer; Urothelial carcinoma; Immunotherapy; Cancer; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005123822,0.0003032647,0.0007477365,0.000216249,0.0001889185,0.0006504327,0.0002039823,0.0002692783,0.001499719],"category_scores_gemma":[0.0004635102,0.0001457923,0.001030426,0.0003059924,0.0001889222,0.0003821389,0.0001985668,0.0007473397,0.0004350367],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003913735,"about_ca_system_score_gemma":0.0003302507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001454059,"about_ca_topic_score_gemma":0.002469572,"domain_scores_codex":[0.9997841,0.00007614373,0.00001237971,0.00004015486,0.00003451571,0.00005270149],"domain_scores_gemma":[0.9997981,0.00004398702,0.00003965688,0.00001726955,0.00001955359,0.00008139749],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.265753,0.01032733,0.2354429,0.00100775,0.005587498,0.0005822611,0.0004624608,0.002933641,0.05835778,0.0002365583,0.01090667,0.4084022],"study_design_scores_gemma":[0.02427347,0.1183425,0.8333827,0.0001374339,0.003432511,0.001028284,0.0003440622,0.00236989,0.006035173,0.000191758,0.01038283,0.00007946392],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9945828,0.002922506,0.0001023945,0.000158852,0.0000360405,0.00003823105,0.0008803934,0.00001805027,0.001260689],"genre_scores_gemma":[0.9939177,0.001618255,0.0002109114,0.0002498727,0.00004211217,0.00003351397,0.002434396,0.00001342594,0.001479901],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001499719,"threshold_uncertainty_score":0.005017042,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05196338569092701,"score_gpt":0.3291695175527266,"score_spread":0.2772061318617995,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}